Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,223,264 papers from all fields of science
Search
Sign In
Create Free Account
taxane 13-alpha-hydroxylase activity
Known as:
taxa-4(20),11-dien-5alpha-ol,NADPH:oxygen oxidoreductase (13alpha-hydroxylating)
, taxane 13a-hydroxylase activity
, taxane 13alpha-hydroxylase activity
Catalysis of the reaction: H(+) + NADPH + O(2) + taxa-4(20),11-dien-5alpha-ol = H(2)O + NADP(+) + taxa-4(20),11-dien-5alpha,13alpha-diol. [EC:1.14.13…
Expand
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
MicroRNA-331-3p inhibits proliferation and metastasis of ovarian cancer by targeting RCC2
Gulimire Buranjiang
,
Reziya Kuerban
,
Ailikemu Abuduwanke
,
Xiaowen Li
,
Gulinar Kuerban
Archives of medical science : AMS
2018
Corpus ID: 81676138
Introduction Epithelial ovarian carcinoma (EOC) is one of the most lethal gynecologic malignancies, with a poor 5-year survival…
Expand
Review
2016
Review
2016
Abstract P4-12-01: Long term follow up of patients (pts) with HER2positive (H+) early stage breast cancer (ESBC) treated with trastuzumab (T)
R. Bose
,
D. Zanoni
,
+9 authors
J. Crown
2016
Corpus ID: 76893902
Background. H+BC is an aggressive variant of BC with earlier and more frequent metastatic relapse than HER2 normal disease…
Expand
Review
2014
Review
2014
Molecular alterations and emerging targets in castration resistant prostate cancer.
D. Lorente
,
J. D. de Bono
European Journal of Cancer
2014
Corpus ID: 30261591
2013
2013
Abstract P2-15-01: Impact of adjuvant trastuzumab (AT) on survival in metastatic (M1) her2 positive breast cancer
C. Lohrisch
,
C. Speers
,
M. Francl
,
S. Tyldesley
2013
Corpus ID: 58731082
Background: Recurrence rates have declined since AT was added to chemotherapy (chx) for her2+ early breast cancer (BC). This has…
Expand
Review
2011
Review
2011
The changing therapeutic landscape of castration-resistant prostate cancer
T. Yap
,
A. Zivi
,
A. Omlin
,
J. Bono
Nature Reviews Clinical Oncology
2011
Corpus ID: 31624435
Castration-resistant prostate cancer (CRPC) has a poor prognosis and remains a significant therapeutic challenge. Before 2010…
Expand
2011
2011
Blinded validation study of genomic predictions for survival following adjuvant sequential anthracycline-docetaxel chemotherapy with or without endocrine therapy.
W. Symmans
,
F. André
,
+9 authors
C. Hatzis
Journal of Clinical Oncology
2011
Corpus ID: 29427908
1030 Background: The adjuvant chemotherapy +/- endocrine survival (ACES) predictor is a microarray-based genomic algorithm that…
Expand
2007
2007
SS8-5 ホルモン抵抗性再燃前立腺癌 (HRPC) に対する Taxane 系抗癌剤、Estramustine、Carboplatin 併用化学療法 (TEC療法)(前立腺再燃癌の機序, 第95回日本泌尿器科学会総会)
浦上 慎司
,
椎名 浩昭
,
+10 authors
井川 幹夫
2007
Corpus ID: 196291313
2003
2003
New taxane diterpenoids from Taiwanese Taxus sumatrana.
Ya‐Ching Shen
,
Yu-Ling Pan
,
+4 authors
Yu-Chi Lin
Chemical and pharmaceutical bulletin
2003
Corpus ID: 25965488
Two new taxane diterpenoids, tasumatrols A (1) and B (2), have been isolated from extracts of the leaves and twigs of Taiwanese…
Expand
2002
2002
Dantaxusins C and D, two novel taxoids from Taxus yunnanensis.
Y. Shinozaki
,
N. Fukamiya
,
+6 authors
K. Lee
Journal of Natural Products
2002
Corpus ID: 9422070
Two new taxane diterpenes, dantaxusin C (1) and dantaxusin D (2), were isolated from an ethanol extract of the aerial parts of…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE